Joaquin Duato and Robert Davis are two of the most prominent executives in the global pharmaceutical industry, leading Johnson & Johnson and Merck, respectively. They are not known to be related or business partners, but they have crossed paths publicly as leaders of competing healthcare companies, most notably when they testified together before the U.S. Senate in February 2024 about prescription drug prices.
As of October 2026, Duato remains Chairman and CEO of Johnson & Johnson, while Robert M. Davis remains Chairman and CEO of Merck & Co. Their careers illustrate two different routes to the top of major healthcare corporations: Duato rose through Johnson & Johnson over several decades, while Davis built experience across Eli Lilly, Baxter and Merck before becoming Merck’s chief executive.
Who Are Joaquin Duato and Robert Davis?
Joaquin Duato and Robert M. Davis oversee companies that compete across important areas of medicine, particularly pharmaceuticals and oncology. Their companies also differ significantly in structure.
Johnson & Johnson operates through Innovative Medicine and MedTech, giving Duato responsibility for a broad healthcare portfolio. Merck is primarily a biopharmaceutical company, with pharmaceutical products, vaccines and a significant animal-health business.
| Executive | Current role | Company | Became CEO |
|---|---|---|---|
| Joaquin Duato | Chairman and CEO | Johnson & Johnson | January 2022 |
| Robert M. Davis | Chairman and CEO | Merck & Co. | July 2021 |
Both later added the chairman position to their CEO responsibilities. Duato became Chairman of Johnson & Johnson in January 2023, while Davis became Chairman of Merck’s board on December 1, 2022.
What Is the Connection Between Joaquin Duato and Robert Davis?
There is no verified evidence of a family relationship, personal partnership or shared corporate position between Joaquin Duato and Robert Davis.
Their documented connection is professional. They run two major U.S. healthcare corporations, operate in many overlapping pharmaceutical markets and participate in industry and public-policy discussions affecting drug manufacturers.
The clearest public event linking their names occurred on February 8, 2024, when both appeared before the U.S. Senate Committee on Health, Education, Labor and Pensions, commonly called the HELP Committee. Bristol Myers Squibb CEO Chris Boerner testified alongside them.
That congressional appearance explains why searches for the two executives together may produce results featuring both names.
The 2024 Senate Hearing That Put Them Together
Why Duato and Davis appeared before Congress
The Senate HELP Committee held a hearing titled “Why Does the United States Pay, by Far, the Highest Prices in the World for Prescription Drugs?”
Its first panel consisted of:
- Joaquin Duato of Johnson & Johnson
- Robert Davis of Merck
- Chris Boerner of Bristol Myers Squibb
The February 8, 2024 hearing focused on U.S. prescription-drug costs, differences between American and overseas pricing, affordability, pharmaceutical research spending and the role of intermediaries such as pharmacy benefit managers.
Their appearance did not result from a corporate collaboration between Johnson & Johnson and Merck. They were invited as chief executives of major drug manufacturers facing similar questions from lawmakers.
The dispute before the hearing
Before the hearing took place, the committee had considered issuing subpoenas to Duato and Davis after they had not initially agreed to appear.
A Senate HELP Committee executive session scheduled for January 31, 2024 included proposed subpoena authorizations for both executives. The session was subsequently cancelled after Duato and Davis agreed to testify voluntarily.
That sequence further connected the two names in congressional records and news coverage.
What Joaquin Duato Said About Drug Pricing
Duato’s prepared Senate testimony argued that pharmaceutical pricing needs to be considered alongside research investment, patient access and the discounts manufacturers provide to other participants in the healthcare system.
He said Johnson & Johnson supported reforms affecting pharmacy benefit managers, or PBMs, and argued that manufacturer rebates and discounts should reach patients more directly. In his prepared statement, Duato said that almost 60% of the list price of Johnson & Johnson medicines in 2022 went toward rebates, discounts and fees.
He also defended a system that rewards medical innovation through patents and regulatory exclusivity. These were Johnson & Johnson’s stated positions, not findings established by the Senate committee.
Lawmakers at the hearing challenged pharmaceutical companies over why some medicines carried substantially higher U.S. prices than prices cited for other countries. The hearing therefore reflected a broader policy disagreement about how responsibility for drug costs should be divided among manufacturers, insurers, PBMs and other parts of the healthcare system.
What Robert Davis Said About Drug Pricing
Davis presented a broadly similar industry argument while speaking specifically for Merck.
Merck said in connection with the hearing that it was concerned about patients struggling with prescription medicine costs and supported ensuring that manufacturer discounts and rebates ultimately benefit consumers. At the same time, Davis emphasized continued U.S. investment in pharmaceutical research and development.
During questioning, senators raised Merck’s pricing of medicines including the cancer therapy Keytruda. Senator Patty Murray, for example, contrasted its U.S. price with a lower figure she cited for Japan. Davis responded that the pricing level referenced for Japan would not be sustainable in the United States.
The exchange illustrates one important similarity between Davis and Duato: both have had to balance arguments about funding pharmaceutical innovation against growing political pressure over patient affordability.
Joaquin Duato’s Career at Johnson & Johnson
Duato’s career is closely tied to one company.
He began working for Johnson & Johnson in 1989 in Madrid, Spain, and subsequently held leadership responsibilities across markets, business units and functions. Before becoming CEO, he served as Vice Chairman of Johnson & Johnson’s Executive Committee and had responsibility that included its pharmaceutical and consumer-health businesses as well as areas such as technology and supply chain.
He became Johnson & Johnson’s eighth CEO in January 2022 and Chairman in January 2023.
Duato holds an MBA from ESADE in Barcelona and a Master of International Management from Thunderbird School of Global Management. He is a dual citizen of Spain and the United States.
Under Duato, Johnson & Johnson has increasingly emphasized six areas:
- Oncology
- Immunology
- Neuroscience
- Cardiovascular medicine
- Surgery
- Vision
Johnson & Johnson describes these areas as central to its current growth strategy.
Robert Davis’s Career Before and at Merck
Davis followed a different career path.
Before joining Merck, he spent approximately 14 years at Eli Lilly and later worked at Baxter, where his positions included chief financial officer, president of the renal business and president of the medical products business.
Davis joined Merck as Chief Financial Officer in 2014. His responsibilities later expanded across areas including corporate strategy, business development, information technology and procurement.
He became:
- Merck President in April 2021
- CEO and a director on July 1, 2021
- Chairman on December 1, 2022
Davis earned a bachelor’s degree in finance from Miami University, a J.D. from Northwestern University Pritzker School of Law and an MBA from Northwestern’s Kellogg School of Management.
Also Read: Gisele Bündchen and Emma Walmsley
Joaquin Duato and Robert Davis as Competing Pharma CEOs
Johnson & Johnson and Merck are separate publicly traded companies. Duato and Davis therefore primarily represent competitors rather than collaborators.
The overlap is especially visible in oncology.
Merck’s Keytruda has become one of the company’s most commercially important products and remains central to its oncology portfolio. Merck reported total worldwide company sales of approximately $65.0 billion in 2025, with oncology among the businesses supporting its performance.
Johnson & Johnson also treats oncology as a core growth area, alongside immunology, neuroscience, cardiovascular care, surgery and vision. Johnson & Johnson reported $94.2 billion in 2025 sales across its broader Innovative Medicine and MedTech businesses.
The numbers should not be interpreted as a direct pharmaceutical-business comparison because Johnson & Johnson includes a substantial medical-device operation that Merck does not have.
Their companies in 2026
The two executives continue to lead businesses with different scales and product mixes.
Johnson & Johnson reported second-quarter 2026 sales of $25.31 billion and said it was targeting more than $100 billion in annual revenue for 2026.
Merck reported second-quarter 2026 worldwide sales of $16.6 billion and projected full-year 2026 sales of approximately $66.3 billion to $67.3 billion at the time of that announcement.
These figures show the scale of the businesses Duato and Davis manage, but differences in their companies’ portfolios mean sales alone are not a meaningful measure of which executive or company is performing “better.”
How Their Leadership Backgrounds Differ
One of the most interesting distinctions between Joaquin Duato and Robert Davis is how each developed the experience that ultimately led to the CEO position.
Duato is essentially a long-term internal Johnson & Johnson executive. His career exposed him to different countries, healthcare divisions and operating responsibilities while remaining within the same corporate organization.
Davis entered Merck after significant experience at other major healthcare companies. His background also includes finance and law, reflected in his earlier CFO responsibilities and his J.D. and MBA qualifications.
In simplified terms, Duato represents a career-insider route to the CEO office, while Davis brought a broader multi-company and finance-oriented background to Merck.
Executive Compensation
Both companies publish executive compensation information through annual shareholder proxy statements, providing a more reliable source than online “net worth” estimates.
Johnson & Johnson’s 2026 proxy reported $27.142 million in 2025 total direct compensation for Duato, consisting primarily of long-term incentives, an annual incentive and salary. His 2026 base salary rate was increased to $1.75 million.
Merck’s 2026 proxy presented approximately $20.80 million in 2025 total annual compensation for Davis, including salary, equity awards, incentive compensation, pension-value changes and other compensation. His year-end 2025 annual base salary was $1.65 million.
Those headline amounts should not be treated as perfectly comparable, because Johnson & Johnson and Merck describe and calculate the displayed compensation measures differently.
Reliable corporate filings also do not provide a definitive personal “net worth” for either executive. Online net-worth estimates may attempt to infer wealth from shares, compensation and transactions, but they cannot account reliably for an individual’s complete assets, liabilities, investments or private finances.
Do Joaquin Duato and Robert Davis Work Together?
There is no evidence that Duato and Davis jointly manage a company or operate a shared business venture.
They can nevertheless participate in the same industry organizations, conferences, policy discussions and healthcare initiatives because both represent major pharmaceutical companies. For example, both are listed among members of the American Heart Association’s CEO Roundtable.
That kind of shared participation is normal for executives whose companies compete commercially while facing many of the same regulatory, scientific and public-health questions.
Why Their Names Are Often Searched Together
Searches for joaquin duato and robert davis are most plausibly explained by their simultaneous Senate appearance rather than any personal relationship.
The February 2024 prescription-drug hearing generated government records, photographs, videos and media reports showing Duato and Davis together. The two had also been connected during the preceding dispute over whether the committee would subpoena them.
The association is therefore straightforward:
Joaquin Duato leads Johnson & Johnson. Robert M. Davis leads Merck. They are competing healthcare executives who have appeared together in high-profile discussions over U.S. pharmaceutical policy and drug pricing.
FAQ
Are Joaquin Duato and Robert Davis related?
No verified public information indicates that Joaquin Duato and Robert M. Davis are related. Their documented connection comes from their leadership positions in the pharmaceutical industry and shared appearances at industry and government events.
What companies do Joaquin Duato and Robert Davis lead?
Joaquin Duato is Chairman and CEO of Johnson & Johnson. Robert M. Davis is Chairman and CEO of Merck & Co., known as MSD outside the United States and Canada.
Did Joaquin Duato and Robert Davis testify together before Congress?
Yes. Both testified before the U.S. Senate HELP Committee on February 8, 2024, during a hearing examining prescription-drug prices in the United States. Bristol Myers Squibb CEO Chris Boerner appeared on the same panel.
Do Johnson & Johnson and Merck compete with each other?
Yes. The companies overlap in major pharmaceutical markets, including oncology, although their overall businesses differ. Johnson & Johnson also operates a large MedTech division, while Merck has businesses including pharmaceuticals, vaccines and animal health.
Who became CEO first, Joaquin Duato or Robert Davis?
Robert Davis became Merck CEO on July 1, 2021. Joaquin Duato became Johnson & Johnson CEO in January 2022.
What is the net worth of Joaquin Duato and Robert Davis?
There is no authoritative public record establishing a precise personal net worth for either executive. Company proxy statements disclose compensation and certain securities information, but that is not enough to calculate complete personal wealth reliably.
Also Read: John Legend and Emma Walmsley
